An in silico transwell device for the study of drug transport and drug-drug interactions.
OBJECTIVE
Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions.


METHODS
We used the synthetic modeling method. Specialized software components represented spatial and functional features including cell components, semi-porous tight junctions, and metabolizing enzymes. Mobile components represented drugs. Experiments were conducted and analyzed as done in vitro.


RESULTS
Verification experiments provided data analogous to those in the literature. ISTD parameters were tuned to simulate and match in vitro urea transport data; the objects representing tight junction (effective radius of 6.66 A) occupied 0.066% of the surface area. That ISTD was then tuned to simulate pH-dependent, in vitro alfentanil transport properties. The resulting ISTD predicted the passive transport properties of 14 additional compounds, individually and all together in one in silico experiment. The function of a two-site enzymatic component was cross-validated with a kinetic model and then experimentally validated against in vitro benzyloxyresorufin metabolism data. Those components were used to exemplify drug-drug interaction studies.


CONCLUSIONS
The ISTD is an example of a new class of simulation models capable of realistically representing complex drug transport and drug-drug interaction phenomena.
Garmire
Lana X
LX
Graduate Group in Comparative Biochemistry, University of California, Berkeley, California, USA.
Garmire
David G
DG
Hunt
C Anthony
CA
D015760:Alfentanil / Q000378:metabolism; D000701:Analgesics, Opioid / Q000378:metabolism; D000818:Animals; D001692:Biological Transport; D020134:Catalytic Domain; D002462:Cell Membrane / Q000378:metabolism*; D003198:Computer Simulation; D004058:Diffusion; D004353:Drug Evaluation, Preclinical / Q000295:instrumentation*; D004347:Drug Interactions; D004798:Enzymes / Q000378:metabolism; D004867:Equipment Design; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008954:Models, Biological; D010078:Oxazines / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D015203:Reproducibility of Results; D012984:Software; D013678:Technology, Pharmaceutical / Q000295:instrumentation*; D019108:Tight Junctions / Q000378:metabolism; D014508:Urea / Q000378:metabolism
D000701:Analgesics, Opioid; D004798:Enzymes; D010078:Oxazines; D004364:Pharmaceutical Preparations; D015760:Alfentanil; C057754:benzyloxyresorufin; D014508:Urea
Biochemistry. 1998 Mar 24;37(12):4137-47
9521735
PLoS Comput Biol. 2006 Oct 6;2(10):e129
17029556
BMC Syst Biol. 2007 Feb 19;1:14
17408504
Int J Pharm. 2005 Apr 11;293(1-2):183-92
15778056
Curr Drug Metab. 2001 Mar;2(1):17-36
11465149
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):27-43
11259831
J Pharmacol Exp Ther. 1999 Nov;291(2):435-43
10525056
Eur J Pharm Sci. 1998 Oct;6(4):325-29
9795090
Science. 2005 Nov 11;310(5750):987-91
16284171
J Pharmacokinet Pharmacodyn. 2006 Dec;33(6):737-72
17051440
J Pharm Sci. 1997 Oct;86(10):1105-10
9344165
Naunyn Schmiedebergs Arch Pharmacol. 1987 Jan;335(1):97-102
3574497
Pharm Res. 1995 Nov;12(11):1573-82
8592653
Curr Top Med Chem. 2001 Sep;1(4):277-351
11899112
Annu Rev Pharmacol Toxicol. 2005;45:291-310
15832445
Pharm Acta Helv. 1996 Nov;71(5):309-27
8973162
Biosystems. 2005 Nov;82(2):154-67
16135397
Biochim Biophys Acta. 2007 Mar;1770(3):360-75
17134838
Pharm Res. 2006 Mar;23(3):493-505
16435171